Literature DB >> 25086658

Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia.

Helena Fatouros-Bergman1, Simon Cervenka2, Lena Flyckt3, Gunnar Edman4, Lars Farde5.   

Abstract

Cognitive deficits represent a significant characteristic of schizophrenia. However, a majority of the clinical studies have been conducted in antipsychotic drug treated patients. Thus, it remains unclear if significant cognitive impairments exist in the absence of medication. This is the first meta-analysis of cognitive findings in drug-naïve patients with schizophrenia. Cognitive data from 23 studies encompassing 1106 patients and 1385 controls published from 1992 to 2013 were included. Tests were to a large extent ordered in cognitive domains according to the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) battery. Analysis was performed with STATA using the random-effects model and heterogeneity as well as Egger's publication bias was assessed. Overall the results show that patients performed worse than healthy controls in all cognitive domains with medium to large effect sizes. Verbal memory, speed of processing and working memory were three of the domains with the greatest impairments. The pattern of results is in line with previous meta-analytic findings in antipsychotic treated patients. The present meta-analysis confirms the existence of significant cognitive impairments at the early stage of the illness in the absence of antipsychotic medication.
Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antipsychotic medication; Cognition; Drug naïve; Meta-analysis; Psychosis; Schizophrenia

Mesh:

Year:  2014        PMID: 25086658     DOI: 10.1016/j.schres.2014.06.034

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  75 in total

1.  Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28.

Authors:  K Collste; P Plavén-Sigray; H Fatouros-Bergman; P Victorsson; M Schain; A Forsberg; N Amini; S Aeinehband; S Erhardt; C Halldin; L Flyckt; L Farde; S Cervenka
Journal:  Mol Psychiatry       Date:  2017-02-14       Impact factor: 15.992

Review 2.  Cognitive inflexibility in Obsessive-Compulsive Disorder.

Authors:  Patricia Gruner; Christopher Pittenger
Journal:  Neuroscience       Date:  2016-08-01       Impact factor: 3.590

3.  Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set.

Authors:  Guillaume Fond; F Berna; L Boyer; O Godin; L Brunel; M Andrianarisoa; B Aouizerate; D Capdevielle; I Chereau; J M Danion; C Dubertret; J Dubreucq; C Faget; F Gabayet; T Le Gloahec; P M Llorca; J Mallet; D Misdrahi; R Rey; R Richieri; C Passerieux; C Portalier; P Roux; A Vehier; H Yazbek; F Schürhoff; E Bulzacka
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-27       Impact factor: 5.270

4.  ERBB4 polymorphism and family history of psychiatric disorders on age-related cortical changes in healthy children.

Authors:  Vanessa Douet; Linda Chang; Kristin Lee; Thomas Ernst
Journal:  Brain Imaging Behav       Date:  2015-03       Impact factor: 3.978

5.  Postnatal MK-801 treatment of female rats impairs acquisition of working memory, but not reference memory in an eight-arm radial maze; no beneficial effects of enriched environment.

Authors:  Masoumeh Nozari; Farshad Alizadeh Mansouri; Mohammad Shabani; Hojat Nozari; Nafiseh Atapour
Journal:  Psychopharmacology (Berl)       Date:  2015-03-07       Impact factor: 4.530

6.  Neurocognitive deficits in schizophrenia are likely to be less severe and less related to the disorder than previously thought.

Authors:  Steffen Moritz; Stephen M Silverstein; Mona Dietrichkeit; Jürgen Gallinat
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

7.  Telomere Length and CCL11 Levels are Associated With Gray Matter Volume and Episodic Memory Performance in Schizophrenia: Evidence of Pathological Accelerated Aging.

Authors:  Leticia Sanguinetti Czepielewski; Raffael Massuda; Bruna Panizzutti; Lucas Kich Grun; Florencia María Barbé-Tuana; Antonio Lucio Teixeira; Deanna M Barch; Clarissa S Gama
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

8.  Psychomotor Slowing in Schizophrenia: Implications for Endophenotype and Biomarker Development.

Authors:  K Juston Osborne; Sebastian Walther; Stewart A Shankman; Vijay A Mittal
Journal:  Biomark Neuropsychiatry       Date:  2020-05-12

9.  Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.

Authors:  Joey W Trampush; Todd Lencz; Pamela DeRosse; Majnu John; Juan A Gallego; Georgios Petrides; Youssef Hassoun; Jian-Ping Zhang; Jean Addington; Charles H Kellner; Mauricio Tohen; Katherine E Burdick; Terry E Goldberg; John M Kane; Delbert G Robinson; Anil K Malhotra
Journal:  Schizophr Bull       Date:  2015-09-25       Impact factor: 9.306

10.  Asperger Syndrome and Schizophrenia: A Comparative Neuropsychological Study.

Authors:  Maria Marinopoulou; Tove Lugnegård; Maria Unenge Hallerbäck; Christopher Gillberg; Eva Billstedt
Journal:  J Autism Dev Disord       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.